What You Should Know:
- PathAI, a provider of AI-powered pathology, and ConcertAIan AI software-as-a-service (SaaS) technology and real-world evidence (RWE) solutions for life sciences and healthcare, today announced a strategic partnership to launch a first-in-class quantitative histopathology and curated clinical real-world data (RWD) solution.
- The solution combines PathAI’s PathExplore™ tumor microenvironment panel with ConcertAI’s Patient360™ and RWD360™ products. Using these products together creates the first, large-scale clinical datasets linking pathology human interpretable features with EMR-derived clinical data, allowing direct insights into current standards of care and treatment dynamics.
- ConcertAI and PathAI will jointly offer these combined solutions to biopharma customers, including translational research and real-world data teams. The initial solutions focus on bladder cancer, colorectal cancer, prostate cancer, and melanoma.